Eli Lilly reported third-quarter earnings and revenue on Thursday that easily surpassed Wall Street’s consensus expectations, driven by surging international and domestic demand for its blockbuster weight-loss medication Zepbound and its leading-edge diabetes treatment Mounjaro. Reflecting this sustained commercial momentum, the pharmaceutical giant dramatically increased its full-year financial outlook for revenue, even as it navigates […]